Efficacy and Safety of TLL-018 in Moderate to Severe Chronic Spontaneous Urticaria Patients with Inadequate Response to H1 Antihistamine: Results from a Phase b Study

被引：0
|
作者：
Lu, Qianjin [1 ]
Yang, Bin [2 ]
Liu, Lunfei [3 ]
Li, Linfeng [4 ]
Liu, Weijun [5 ]
Yao, Xu [1 ]
Man, Xiaoyong [6 ]
Chen, Aijun [7 ]
Shi, Yuling [8 ]
Ding, Yangfeng [8 ]
Sun, Qing [9 ]
Tao, Juan [10 ]
Liang, Chris [11 ]
Liu, Yong [11 ]
Liu, Donghua [11 ]
Sun, Peiyu [11 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Dermatol, Beijing, Peoples R China
[2] Southern Med Univ, Dermatol Hosp, Guangzhou, Peoples R China
[3] Zhejiang Univ, Sch Med, Affiliated Hosp 4, Hangzhou, Peoples R China
[4] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China
[5] Dermatol Hosp Jiangxi Prov, Nanchang, Jiangxi, Peoples R China
[6] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[7] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China
[8] Tongji Univ, Sch Med, Shanghai Skin Dis Hosp, Shanghai, Peoples R China
[9] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[10] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[11] Hangzhou Highlightll Pharmaceut Co Ltd, Hangzhou, Peoples R China
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
L36
引用
收藏
页码：AB372 / AB372
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase III, JADE MONO-1 study
    Simpson, E. L.
    Sinclair, R.
    Forman, S.
    Wollenberg, A.
    Asch, R.
    Cork, M.
    Bieber, T.
    Thyssen, J. P.
    Yosipovitch, G.
    Magnolo, N.
    Maari, C.
    Flohr, C.
    Feeney, C.
    Biswas, P.
    Tatulych, S.
    Valdez, H.
    Rojo, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E105 - E106
  • [32] Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Final phase IIIb study results
    Gottlieb, A
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P1 - P1
  • [33] Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
    Strober, B. E.
    Crowley, J. J.
    Yamauchi, P. S.
    Olds, M.
    Williams, D. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (03) : 661 - 668
  • [34] Efficacy and safety of methotrexate versus placebo as add-on therapy to H1 antihistamines for patients with difficult-to-treat chronic spontaneous urticaria: A randomized, controlled trial
    Leducq, Sophie
    Samimi, Mahtab
    Bernier, Claire
    Soria, Angele
    Amsler, Emmanuelle
    Staumont-Salle, Delphine
    Gabison, Germaine
    Chosidow, Olivier
    Beneton, Nathalie
    Bara, Corina
    Grange-Prunier, Anne
    Wierzbicka-Hainaut, Ewa
    Brenaut, Emilie
    Droitcourt, Catherine
    Raison-Peyron, Nathalie
    Bourgoin, Helene
    Cornillier, Helene
    Machet, Laurent
    Giraudeau, Bruno
    Caille, Agnes
    Maruani, Annabel
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (01) : 240 - 243
  • [35] REMIBRUTINIB SHOWED GOOD STABILITY OF RESPONSE IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY
    Tillinghast, J.
    Jain, V.
    Maurer, M.
    Gimenez-Arnau, A.
    Reich, A.
    Ortmann, C.
    Walsh, P.
    Haemmerle, S.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S41 - S41
  • [36] Ligelizumab as add-on therapy for patients with H1-antihistamine-refractory chronic spontaneous urticaria: primary results of a placebo- and active-controlled phase 2b dose-finding study
    Maurer, M.
    Gimenez-Arnau, A.
    Sussman, G.
    Loeffler, J.
    Barve, A.
    Severin, T.
    Janocha, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 121 - 121
  • [37] Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study (vol 135, pg 67, 2015)
    Saini, Sarbjit S.
    Bindslev-Jensen, Carsten
    Maurer, Marcus
    Grob, Jean-Jacques
    Baskan, Emel Buelbuel
    Bradley, Mary S.
    Canvin, Janice
    Rahmaoui, Abdelkader
    Georgiou, Panayiotis
    Alpan, Oral
    Spector, Sheldon
    Rosen, Karin
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 (03) : 925 - 925
  • [38] The safety and efficacy of omalizumab in chronic idiopathic/spontaneous urticaria: results from a phase III randomised, double-blind, placebo-controlled study
    Maurer, M.
    Staubach, P.
    Ashby, M.
    Canvin, J.
    Ledford, D.
    Kaplan, A.
    Jakob, T.
    Rosen, K.
    ALLERGY, 2013, 68 : 704 - 704
  • [39] REMIBRUTINIB IMPROVES CHRONIC SPONTANEOUS URTICARIA IN PATIENTS IRRESPECTIVE OF CU-INDEX: RESULTS FROM PHASE 2B STUDY
    Carr, W.
    Sitz, K.
    Jain, V.
    Gimenez-Arnau, A.
    Lheritier, K.
    Nikolaev, L.
    Haemmerle, S.
    Maurer, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S11 - S11
  • [40] Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1)
    Igarashi, Atsuyuki
    Nakagawa, Hidemi
    Morita, Akimichi
    Okubo, Yukari
    Sano, Shigetoshi
    Imafuku, Shinichi
    Tada, Yayoi
    Honma, Masaru
    Mendelsohn, Alan M.
    Kawamura, Masaki
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 853 - 863
12345